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Effect of HPV vaccination and cervical cancer screening in 
England by ethnicity: a modelling study
Helen C Johnson, Erin I Lafferty, Rosalind M Eggo, Karly Louie, Kate Soldan, Jo Waller, W John Edmunds
Summary
Background Health equality is increasingly being considered alongside overall health gain when assessing public 
health interventions. However, the trade-off between the direct effects of vaccination and herd immunity could lead to 
unintuitive consequences for the distribution of disease burden within a population. We used a transmission dynamic 
model of human papillomavirus (HPV) to investigate the effect of ethnic disparities in vaccine and cervical screening 
uptake on inequality in disease incidence in England.
Methods We developed an individual-based model of HPV transmission and disease, parameterising it with the latest 
data for sexual behaviour (from National Survey of Sexual Attitudes and Lifestyles [Natsal-3]) and vaccine and 
screening uptake by ethnicity (from Public Health England [PHE]) and fitting it to data for HPV prevalence (from 
ARTISTIC, PHE, Natsal-3) and HPV-related disease incidence (from National Cancer Registry [ONS]). The outcome 
of interest was the age-adjusted incidence of HPV-related cancer (both cervical and non-cervical) in all women in 
England in view of differences and changes in vaccination and screening uptake by ethnicity in England, over time. 
We also studied three potential public health interventions aimed at reducing inequality in HPV-related disease 
incidence: increasing uptake in black and Asian females to match that in whites for vaccination; cervical screening in 
women who turn 25 in 2018 or later; and cervical screening in all ages.
Findings In the pre-vaccination era, before 2008,  women from ethnic minorities in England reported a disproportionate 
share of cervical disease. Our model suggests that Asian women were 1·7 times (95% credibility interval [CI] 1·1–2·7) 
more likely to be diagnosed with cervical cancer than white women (22·8 vs 13·4 cases per 100 000 women). Because 
HPV vaccination uptake is lower in ethnic minorities, we predict an initial widening of this gap, with cervical cancer 
incidence in Asian women up to 2·5 times higher (95% CI 1·3–4·8) than in white women 20 years after vaccine 
introduction (corresponding to an additional 10·8 [95% CI 10·1–11·5] cases every year). In time, we predict that herd 
immunity benefits will diffuse from the larger white sub-population and the disparity will narrow. Increased cervical 
screening uptake in vaccinated women from ethnic minorities would lead to rapid improvement in equality with 
parity in incidence after 20 years of HPV vaccination.
Interpretation Our study suggests that the introduction of HPV vaccination in England will initially widen a pre-
existing disparity in the incidence of HPV-related cancer by ethnicity, partly due to herd immunity disproportionately 
benefiting subgroups with high vaccination rates. Although in time this induced disparity will narrow, increasing 
cervical screening uptake in girls from ethnic minorities should be encouraged to eliminate the inequality in cervical 
cancer incidence in the medium term. We recommend that dynamic effects should be considered when estimating 
the effect of public health programmes on equality.
Funding Cancer Research UK.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
HPV infection is implicated in more than 99% of 
cervical cancer cases1 with roughly 70% caused by types 
HPV-16 and HPV-18.2 Since 2006, two highly effective 
prophylactic vaccines against HPV-16 and HPV-18 
have been available worldwide3 and cervical screening 
remains an effective secondary prevention strategy. 
HPV infection has also been implicated in some anal, 
genital, and head and neck cancers.3
In 2008, the UK initiated school-based vaccination of 
12–13 year-old-girls, with more than 86% of girls receiving 
a full course of vaccination between 2012 and 2014.4 
However, findings of demographic studies have 
consistently reported substantially higher levels of 
vaccination uptake in white girls than in those from 
minority ethnic backgrounds.5,6 An equivalent disparity is 
reported in cervical screening attendance: white women 
are more than twice as likely to have attended screening 
as women of another ethnic origin.7,8 Indeed, a positive 
association has been recorded between uptake of 
vaccination and of cervical cancer screening in both 
empirical9,10 and survey-based5,9 studies in the UK. 
Herd immunity, the indirect protection afforded to 
unvaccinated individuals through reduced pathogen 
circulation, might mitigate this effect. However, findings 
of a recent study have shown clear patterns of so-called 
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like-with-like sexual mixing (ie, choosing a sexual partner 
like oneself) by ethnicity in Britain,11 raising concerns 
that the herd immunity benefit might be concentrated in 
ethnic subgroups with high HPV vaccination rates.
To understand the complicated nature of infection 
dynamics and disease progression, and the multiple 
behavioural and demographic factors such as those 
associated with HPV and cervical cancer, mathematical 
models are often used.12–14 Recent studies have considered 
the hypothetical effect of HPV vaccination on health 
inequality14–17 and others have questioned the implications 
of difference in vaccination uptake by ethnicity;18,19 
however, none to our knowledge have made a data-based 
evaluation of the implicit dependency of sexual mixing 
and health-care-seeking behaviour.
We developed an individual-based model of HPV 
infection, cervical disease, and HPV-attributable non-
cervical cancer in England, parameterising it with the 
latest ethnicity-stratified data on sexual behaviour and 
vaccination and screening uptake. Here we describe the 
development, parameterisation, and fitting of the model to 
data on HPV prevalence and incidence of cervical disease 
and non-cervical cancers; make predictions of the 
consequences of HPV vaccination on health equality over 
time; and estimate the effect of three potential public 
health interventions aiming to reduce inequality in HPV-
related disease incidence.
Methods
Study design
We developed a generic individual-based sexually 
transmitted infection model20 to simulate heterosexual 
partnership formation on the basis of sexual activity and 
ethnicity, multi-type HPV transmission and disease 
progression, cervical screening, and HPV vaccination. 
The outcome of interest was the incidence of age-adjusted 
HPV-related cancer incidence (both cervical and non-
cervical, using the European Standard Population) in view 
of differences and changes in vaccination and screening 
uptake by ethnicity. The model was coded in C++ and 
implemented on the Amazon Web Services EC2 service as 
a virtual cluster on a StarCluster platform (version 0.95.6). 
Statistical analysis was done with Stata (version 12) and R 
(version 3.1.1).
Parameterisation
We parameterised the model with demographic data 
from the Office for National Statistics (ONS)21–23 and 
behavioural data from the latest National Survey of Sexual 
Attitudes and Lifestyles (Natsal-3).24–27 We fitted the model 
to age-specific HPV prevalence data obtained from: 
Natsal-3; Public Health England (PHE) surveillance of 
HPV in young women attending chlamydia screening;28 a 
PHE study of women attending cervical screening;29 and a 
randomised trial of cytological testing in women 
attending routine cervical screening (ARTISTIC).30 To 
account for biases in the underlying subpopulations, we 
used a Bayesian evidence synthesis approach to estimate 
the true type-specific prevalence of HPV in the population 
(appendix p 20). We obtained data for cervical disease 
prevalence by age and type from the ARTISTIC study. 
Data for age-dependent incidence of carcinoma in situ of 
cervix uteri and of HPV-related cancers was obtained 
from the National Cancer Registry (ONS). Attribution of 
carcinoma in situ of cervix uteri and cancer by HPV type 
was made according to the proportion of histological 
samples testing positive for each type in the case of 
cervical cancer (appendix p 14); data from PHE) and 
See Online for appendix
Research in context
Evidence before this study
We searched PubMed on Sept 16, 2017, with no language or 
date restrictions for articles seeking to quantify the effects of 
HPV vaccination on health equality with the following search 
terms: “HPV”, “model OR model(l)ing”, and “(in)equity OR (in)
equality”. In the past 5 years, modelling studies have suggested 
that HPV vaccination might cause an increase in health 
inequality but we found none that used behavioural data to 
assess the interplay between sexual mixing and 
health-care-seeking behaviour.
Added value of this study
We modelled the interdependency between sexual mixing and 
vaccination and screening uptake, using data stratified by 
ethnicity. Data suggest that people are more likely to choose 
sexual partners from within a group with shared patterns of 
health-seeking behaviour. We believe this to be the first study 
to base the evaluation of the dynamic effects of such 
like-with-like mixing on behavioural data. Our modelling 
study suggests that the introduction of the HPV vaccine in 
England will initially widen a pre-existing disparity in the 
incidence of HPV-related cancer by ethnicity. We predict that 
over time herd immunity effects will redress this gap at a rate 
dependent on the degree to which sexual partnerships are 
formed between groups. We show that increasing cervical 
screening uptake among vaccinated girls from ethnic 
minorities could eliminate the inequality in cervical cancer 
incidence within 30 years.
Implications of all the available evidence
The case study of HPV, cancer, and ethnicity highlights 
important factors in assessing the effect on health equality of 
new and existing public health programmes. Our modelling 
analysis shows that the interplay of infection dynamics with 
disparities in vaccination and screening uptake could lead to 
increased health inequality. We recommend that dynamic 
modelling studies, parameterised with behavioural data, be 
used to better understand these trade-offs.
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according to the scientific literature31–33 for non-cervical 
cancer (appendix p 15).
Model structure
The model population (n=100 000) was split by sex (50:50) 
and ethnicity (white [88·8%], black [3·4%], and 
Asian [7·8%]).34 Each individual belonged to one of nine 
age groups and one of two sexual activity groups (because 
HPV is highly prevalent, we assumed its transmission 
was not driven by smaller core groups). For each age 
group, the high sexual activity group was parameterised 
with the characteristics of the 15% of NATSAL-3 
respondents reporting the highest number of partners in 
the preceding year. We ran 100 simulations of the model 
for each scenario, giving an effective population size of 
10 000 000 yet allowing for computational parallelisation.
For partnership formation, we modelled three types of 
non-concurrent heterosexual partnership: casual, steady, 
and married or cohabiting. Partnership formation 
followed a female demand model.20 The age and sexual 
activity group of the female partner determined both the 
delay before a new partnership was formed and the 
partnership type. Partnership type determined partner 
choice (by age and ethnicity) and partnership duration.
We modelled 13 high-risk HPV types (–16, –11, –31, 
–33, –35, –39, –45, –51, –52, –56, –58, –59, and –68) and 
two low-risk type (–06, –11). High-risk types could 
potentially progress to either squamous cell carcinoma 
or adenocarcinoma via three stages of intraepithelial 
neoplasia (CIN1-3 and CGIN1-3, respectively) and a stage 
of carcinoma in situ. We established the branching 
fraction of each type towards squamous cell carcinoma 
versus adenocarcinoma by the proportion of cancer type 
attributed to each HPV type29 (appendix p 14). We 
assumed that type-specific naturally-acquired immunity 
was lifelong. Additionally, we modelled, with competing 
risks, the progression of high-risk HPV infection to non-
cervical (anal, oropharyngeal, laryngeal, penile, and 
vulval or vaginal) cancers. We estimated type-specific 
transmission proba bilities and progression and clearance 
rates as part of the model-fitting process. The appendix 
provides flowcharts of the natural history of infection 
and disease progression (appendix pp 12, 13) and 
posterior values of estimated parameters (appendix 
pp 34–38).
We implemented the National Health Service (NHS) 
protocol for England (appendix p 17)35 in which women 
are invited for cervical screening every 3 years between 
the ages of 25 and 49 years and every 5 years between the 
ages of 50 and 64 years. We specified the proportion of 
women who were full, partial, or non-attendees of 
cervical screening by ethnicity according to Natsal-3 data. 
PHE data suggested lower uptake across all ethnic 
groups than Natsal-3 and a larger discrepancy between 
white and black and Asian women (figure 1A). Stage-
dependent sensitivity and specificity estimates for 
cervical screening were obtained from a UK-specific 
literature review (appendix p 16).36,37 We assumed the 
odds ratio for cervical screening attendance in vaccinees 
was 1·6, in line with a school-based study of screening 
intention5 and early findings from Wales9 and Scotland,10 
in which women were invited for screening from the age 
of 20 years.
Figure 1:  Uptake of cervical screening and HPV vaccination by ethnicity
Cervical screening attendance by ethnicity as estimated by Natsal-3 and Public 
Health England (A). We termed “recent” screening to be within the past 5 or past 
10 years for those younger or older than 50 years, respectively, thereby including 
women who were overdue a routine appointment. Uptake of HPV vaccination for 
the routine cohort and two catch-up cohorts, by ethnic group based on data 
obtained from the clinical practice research datalink (B) and primary care trusts (C). 
Bar height shows proportion of women receiving at least one dose; light blue 
shows the subset fully vaccinated.
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We implemented the UK vaccination programme, 
vaccinating a routine cohort (aged 12–13 years) once a 
year from 2008 and two catch-up cohorts (aged 14–15 years 
and 16–18 years) between 2009 and 2011 with three doses 
of bivalent Cervarix (administered at 0, 1, and 6 months). 
From 2012, the vaccine changed to the quadrivalent 
Gardasil (administered at 0, 2, and 6 months), reducing to 
two doses in 2014. Data for HPV vaccination uptake by 
ethnicity were obtained from eight child health databases 
stored at the clinical practice research datalink and the 
primary care trusts (figure 1B, C). In the routine cohort, 
more than 80% of girls had initiated HPV vaccination 
and more than 70% of girls had completed HPV 
vaccination. However, in the 16–18-year-old catch-up 
cohort, coverage was much lower with fewer than 60% of 
girls initiating HPV vaccination. In all cohorts, white girls 
were more likely to have initiated or completed 
vaccination than girls of black or Asian ethnicity. We used 
the primary care trust data to parameterise the model 
because the clinical practice research datalink data can be 
less representative because of delays in database updating.
We considered the efficacy of two or three doses of 
either bivalent or quadrivalent vaccine against persistent 
HPV-16 and HPV-18 infection to be 95% with reduced 
protection offered by one dose (90% efficacy).38,39 We 
assumed protection to last precisely 20 years (sensitivity 
analysis of lifelong protection is reported in the appendix 
[p 21]). We also modelled cross-protection of both 
vaccines against non-vaccine types to range between 18% 
and 79%, according to the levels estimated by Wheeler 
and colleagues40 and Malagon and colleagues41 (appendix 
p 18), assuming the duration of cross-protection to be 
shorter (10 years).
For model fitting we used a sequential Monte Carlo 
approach to estimate transmission probability and rates 
of disease progression and clearance for each HPV type, 
assuming that transmission probability and rate of 
clearance of initial infection to be the same for men as 
for women. Rates of progression to non-cervical cancers 
were allowed to differ between men and women. For 
each scenario, we ran the model for the 100 best-fitting 
parameter sets.
For intervention analyses we modelled alternative 
scenarios to assess interventions that might reduce 
inequality. We considered intervening 10 years after 
vaccine introduction (2018), increasing black and Asian 
uptake to match white uptake for: vaccination; cervical 
screening for women who turn 25 in 2018 or later; and 
cervical screening for all ages.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results 
Our model predicts that the age-standardised incidence of 
cervical cancer will initially remain stable for roughly 
10 years before falling sharply, with a time lag of 20 years 
to achieve an overall 50% reduction in the age-standardised 
incidence of cervical cancer after 30 years. We esti mated a 
long-term equilibrium incidence of roughly 4·4 cases of 
cervical cancer per 100 000 women per year (figure 2A) 
These residual cases were caused by non-vaccine HPV 
types. Incidence of HPV-attributable non-cervical cancer 
(including anal, oropharyngeal, laryngeal, vulval, vaginal, 
and penile cancer) decreased more slowly because of 
slower progression to disease, but we estimate that 
Figure 2: Model-predicted incidence of cancer by ethnicity, over time
(A) Annual incidence of cervical cancer per 100 000 white, black, and Asian women. (B) Annual incidence of HPV-attributable non-cervical cancer per 
100 000 members of the white, black, and Asian populations. Bar height shows the mean model output for 100 simulations, the error bars the 95% credibility 
interval.
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50 years after the introduction of the HPV vaccine to girls, 
the incidence of such cancer will fall to 55% of its original 
level in both men and women (figure 2B).
In the pre-vaccination era, our model suggests that 
cervical cancer incidence was 1·7 times (95% credibility 
interval [CI] 1·1–2·7) higher in the Asian than the white 
population. In absolute terms, this corresponds to an 
additional 8·5 (7·9–9·1) cases of cervical cancer per 
100 000 women-years. After HPV vaccine introduction 
in 2008, we predict the inequality in cancer incidence 
between these two groups will become greater 
(figures 3A and 4A). By 2027, 20 years after vaccine 
introduction, the incidence rate of cervical cancer will be 
2·5 times higher among Asian than white women 
(95% CI 1·3–4·8), corresponding to an additional 10·8 
(95% CI 10·1–11·5) cases annually. However, more than 
20 years after vaccine introduction, we predict the rate 
ratio of cervical cancer incidence will reduce. 50 years 
after vaccine introduction, we estimate incidence in 
Asian women will be only 1·9 times as high as in white 
women (95% CI 0·97–3·6). Our analysis suggests 
that cervical cancer incidence is higher in the black 
population than amongst their white counterparts, with 
a similar pattern of increasing disparity in the first 
20–30 years, followed by a decrease (figure 3B). However, 
these results were not statistically significant in our 
modelled population at the 95% credibility level.
Findings of our intervention analysis showed that 
interventions to reduce inequality in cervical disease 
should focus on aiming for parity in either HPV vac-
cination or cervical screening uptake. We predict a 2018 
campaign raising vaccination uptake in black and Asian 
girls to levels of their white peers would have little effect 
on distribution of incident cervical cancer over the 
following 40 years (figures 3 and 4). However, an 
intervention achieving equivalent rates of cervical 
screening attendance between black and Asian women 
from the routine vaccination cohort and their white 
counterparts will lead to a more rapid reduction in 
the inequality, reaching pre-vaccination levels 18 and 
22 years after the intervention for black and Asian 
women, respectively. Indeed, 30 years after vaccine 
introduction, the distribution of incident cervical cancer 
would be more equitable than in the pre-vaccination era. 
A 2018 inter vention resulting in cervical screening 
uptake among black and Asian women of all ages 
matching that of white women would cause a rapid 
correction in inequality and after 20 years the ethnic 
inequality in cervical disease would be overcome, 
overcoming the ethnic inequality completely after 12 and 
20 years, respectively, for black and Asian women.
Discussion
Data from our modelling analysis suggest that due to 
differences in sexual behaviour (including a tendency to 
choose partners from a similar background as oneself ) 
and uptake of cervical screening, ethnic minorities in 
the UK are disproportionately affected by HPV-related 
disease, including cancer. Because uptake of HPV 
vaccination has been lower in black and Asian girls than 
in white girls, we predict that there will be increased 
inequality in HPV-attributable cancer incidence between 
ethnic minorities over the medium term (in both 
absolute and relative terms).
Initially, the consequences of the HPV vaccination 
programme are dominated by the direct protection of 
vaccinated girls themselves. Because vaccination uptake 
in both routine and catch-up cohorts was higher among 
white girls, more cancer cases were averted in this sub-
population per person than in black and Asian groups. 
However, over time, indirect effects will also affect cancer 
incidence. Our modelling analysis suggests that between 
20 and 50 years after vaccine introduction, the incidence 
Figure 3: Rate ratios of model-predicted cervical cancer incidence over time 
comparing (A) Asian with white women and (B) black with white women
Figure shows the effect of HPV vaccination introduction as our base case 
scenario, together with three potential interventions for addressing the 
resultant increase in inequality. We estimated the effect of increasing ethnic 
minority uptake of HPV vaccination, cervical screening in the routine vaccination 
cohort, and cervical screening of all ages to match the levels observed in the 
white sub-population. Interventions were made in 2018 (10 years after the 
introduction of the HPV vaccine).
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rate ratio will fall once more until cervical cancer 
incidence in Asian girls is around 1·9 times that in white 
girls. Here we see the effect of the herd immunity effect: 
as the prevalence of HPV circulating in the overall 
population is reduced, the number of infections in 
unvaccinated girls of all ethnicities is also reduced and 
consequently so is HPV-related disease incidence. In the 
long term, the protective effect of herd immunity will 
overcome the discrepancy in vaccination uptake.
However, our analysis also showed that even if HPV 
vaccination uptake were increased among black and 
Asian girls to levels of their white peers, cohort effects 
and slow progression to cancer would cause the induced 
inequality to persist for at least 40 years following the 
intervention. To reduce the resultant inequality more 
rapidly, it would be necessary to address the difference in 
cervical screening uptake, thus protecting the unvac-
cinated. Although it might be easier to encourage 
vaccinees to attend cervical screening, this would lead to 
an even greater concentration of unprotected women in 
the subgroup which is neither vaccinated not screened. It 
might be preferable to actively seek out unvaccinated 
women to attend cervical screening.
This work builds on a number of other studies that 
have raised the question of how differences in uptake of 
vaccination and cervical screening will affect equality in 
HPV-related disease outcomes. Initial explorations 
considered hypothetical cases of increasing assortative 
mixing (assortativity) in partner choice,14–17 others used 
ethnicity-specific data on vaccination and screening 
uptake but did not consider sexual mixing.18,19 The 
strength of this study lies in the data-grounded 
modelling approach: by using an individual-based 
transmission dynamic model, we have been able to 
incorporate heterogeneity in both sexual and health-
protective behaviour by ethnicity, including detailed 
data on partner choice by ethnicity and age, and to track 
an individual’s life history of infection, vaccination, and 
disease. Uptake of both HPV vaccination and cervical 
screening has been associated with social deprivation 
in the UK. However, we chose to focus on ethnic 
heterogeneity due to the availability of sexual behaviour 
(in particular, mixing) data by ethnicity.
Our study also has limitations. In line with other HPV 
modelling studies, we make the simplifying assumption 
that neither sexual behaviour nor health-protective 
behaviour varies demographically over time. In fact, the 
three rounds of Natsal have documented significant time 
trends, for example showing increasingly younger sexual 
début.25 It would be pertinent to this study to better 
understand relative rates of sexual behaviour change 
between ethnic groups and also the association between 
changes in sexual behaviour and screening and vaccination 
uptake. If behaviour becomes more similar between ethnic 
groups, or if assortativity in partner choice decreases, 
inequality of disease incidence might naturally decrease.
Second, we consider only three ethnic groups, belying 
more complex behavioural heterogeneity. For example, 
88% of people were classified as white, including a 
substantial (and growing) proportion of non-UK born 
individuals about whose vaccination and screening 
behaviour we know relatively little. Furthermore, we did 
not model migration. The effect of migration on health 
equality will depend on the relative rates of screening and 
vaccination uptake compared with the native population 
and on sexual mixing choices. If migrant populations 
choose partners from within their own communities or 
have a relatively low uptake of public health interventions, 
inequality might be increased further. Furthermore, we 
only modelled two sexual activity groups because we 
assumed that the high pre valence of HPV implies its 
dynamics are not driven by a highly active core group.
Figure 4: Absolute difference in model-predicted cervical cancer incidence per 100 000 women over time comparing (A) Asian with white women and 
(B) black with white women
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We made some limiting assumptions about the natural 
history of HPV. First, we assumed that the infection 
with one HPV type offers lifetime protection against 
reinfection with the same type. In forthcoming work, we 
will reassess this assumption in line with a recent 
review.42 Second, we assumed that higher-grade lesions 
(CIN2+) do not spontaneously regress and can be 
diagnosed with certainty. This assumption belies the 
clinical challenges of cytological categorisation but, 
because we fit the model to data on cervical cancer and 
carcinoma in situ, should not detract from our findings 
about changes in inequality of cancer incidence.
Discussion about the cost-effectiveness of including 
boys in the UK HPV vaccination programme is ongoing. 
Although achieving parity in HPV vaccination uptake 
between girls of different ethnicities might not address 
the increased inequality in cervical cancer incidence, 
increasing overall vaccine coverage by vaccinating boys 
could heighten the herd effect sufficiently to hasten its 
reduction. The appendix provides our preliminary yet 
inconclusive consideration of this issue (appendix p 22).
Future work should consider the marginal effect on 
ethnic inequality associated with the introduction of 
HPV testing as a primary test of HPV infection in view of 
indications of early studies that psychological burden 
of infection is associated with social and cultural norms.43
In conclusion, the case study of HPV, cancer, and 
ethnicity highlights important factors in assessing the 
effect on health equality of new and existing public 
health programmes. Public health interventions should 
aim to provide not only a population-level health gain 
but also to maintain, preferably improve, the level of 
equality, whether on the basis of socioeconomic status, 
ethnicity, or age. Our modelling analysis shows that the 
interplay of infection dynamics with disparities in health-
protective behaviour can be unintuitive. Direct 
vaccination benefits will mirror differences in vaccination 
uptake between groups. Additional herd immunity 
benefits will be de pendent on the degree to which 
subgroups mix and the extent to which their behaviour 
differs. We recommend dynamic effects should be 
considered when estimating the effect of vaccination and 
screening programmes on health inequality and in 
planning its minimisation
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